PRKCD and Sepsis: Utilizing both in vivo (rat CLP model) and in vitro (B3C) tools, our findings support a novel therapeutic paradigm that targets PKCδ and neutrophil-endothelial interactions to protect BBB integrity and attenuate sepsis-induced brain tissue damage.